Skip to main
XGN

Exagen Inc (XGN) Stock Forecast & Price Target

Exagen Inc (XGN) Analyst Ratings

Based on 6 analyst ratings
Strong Buy
Strong Buy 67%
Buy 33%
Hold 0%
Sell 0%
Strong Sell 0%

Bulls say

Exagen Inc. has demonstrated a robust performance, with average selling prices (ASPs) for its testing products increasing to $441 per test, reflecting a year-over-year growth of 9%, indicating a positive trend in pricing strategy. The company's revenue has also seen a notable increase of 19% year-over-year on a nine-month basis, supported by balanced growth in both ASPs and test volumes, showcasing their effective market penetration among community rheumatologists. Furthermore, Exagen's strategic expansion plans—including an increase in sales territories and leadership changes within the commercial team—position the company well for sustained volume growth and operational success moving forward.

Bears say

Exagen Inc's stock outlook is negatively impacted by a revised growth forecast for 2026, which reflects delayed positive free cash flow and a decline in peer multiples, leading to a price target reduction from $18 to $8. The company experienced a significant stock drop of over 60% following the 3Q25 results, largely due to the loss of a direct bill account that represented 2% of total volume, raising concerns about overall growth and profitability timelines. Furthermore, Exagen has reduced its workforce by approximately 42 full-time equivalents across sales, R&D, and other functions, resulting in lower revenue per sales territory compared to previous quarters.

Exagen Inc (XGN) has been analyzed by 6 analysts, with a consensus rating of Strong Buy. 67% of analysts recommend a Strong Buy, 33% recommend Buy, 0% suggest Holding, 0% advise Selling, and 0% predict a Strong Sell.

This aggregate rating is based on analysts' research of Exagen Inc and is not a guaranteed prediction by Public.com or investment advice.

Order type

Buy in

Order amount

Est. shares

0 shares

Sign up to buy

FAQs About Exagen Inc (XGN) Forecast

Analysts have given Exagen Inc (XGN) a Strong Buy based on their latest research and market trends.

According to 6 analysts, Exagen Inc (XGN) has a Strong Buy consensus rating as of Feb 4, 2026. This rating is provided by third-party analysts and is not investment advice from Public.com.

Wall Street analysts have set a price target of $12, reflecting a 0.00% increase from the current stock price.

Financial analysts have set a price target of $12, indicating a 0.00% increase from the current stock price, but ratings and forecasts are frequently updated based on market conditions, earnings reports, and industry trends. This prediction is provided by third-party analysts and is not investment advice from Public.com.

Exagen Inc (XGN)


Order type

Buy in

Order amount

Est. shares

0 shares

Sign up to buy
Disclaimer: Any investment listed here, which may be available on the Public platform, is intended to be used for informational purposes only, should not be the sole basis for making an investment decision, and is not a recommendation or advice.